after adjustment for age, tumor characteristics, and treatment selection, both post-diagnostic and pre-diagnostic statin use were associated with lowered risk of breast cancer death (hr 0.46, 95% ci 0.38–0.55 and hr 0.54, 95% ci 0.44–0.67, respectively).